Artificial neural networks in urology: Update 2000

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue 5-6, 1999, Pages 222-226

  Reckwitz, T ^a   Potter, S R ^a   Snow, P B ^b   Zhang, Z ^c   Veltri, R W ^d   Partin, A W ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b Xaim Inc   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UroCor Incorporated   (United States)

Author keywords

Detection; Neural Network; Outcomes; Prostate cancer; Staging

Indexed keywords

ALGORITHM; ARTIFICIAL NEURAL NETWORK; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED IMPEDANCE TOMOGRAPHY; DEMOGRAPHY; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; UROLOGY;

EID: 0033505274     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500374     Document Type: Review

References (34)

1. Snow PB, Smith DS, Catalona WJ. Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol 1994; 152: 1923-19260.
2. Stamey TA et al. Effectiveness of ProstAsure in detecting prostate cancer (PCa) and benign prostatic hyperplasia (BPH) in men age 50 and older. J Urol 1996; 155(Suppl): 436A.
3. Stamey TA et al. A neural network (ProstAsure™) with high sensitivity and specificity for diagnosing prostate cancer (PCa) in men with a PSA J Urol 1997; 157(Suppl): 364.
4. Babaian RJ et al. Evaluation of the ProstAsure Index in the detection of prostate cancer: a preliminary report. Urology 1998; 51: 132-136.
5. Zhang Z et al. A comparison of percent free-PSA and ProstAsure™ index in separating prostate cancer from BPH and normal in men with a PSA level between 2.5-4.0ng/ml. J Urol 1998; 159(Suppl.): 109.
6. Stamey TA et al. A neural network (ProstAsure™) with sensitivity and specificity of 75% in detecting prostate cancer in men with a PSA J Urol 1998; 159(Suppl.): 72.
7. Tewari A et al. Genetic adaptive neural network model to predict outcome of needle biopsy in 3773 patients with elevated PSA. J Urol 1999; 161(Suppl): 326.
8. Snow PB et al. Evaluation of an artificial neural network for the determination of the probability of prostate cancer prior to biopsy. J Urol 1999; 161(Suppl): 210.
9. Douglas TH et al. Neural network analysis of pre-operative and postoperative variables to predict pathologic stage and recurrence following radical prostatectomy. J Urol 1996; 155(Suppl): 487A.
10. Tewari A, Narayan P. Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks. J Urol 1998; 160: 430-436.
11. Miller MC et al. Logistic regression and Artificial Neural Networks (ANNs) in the prediction of pre-operative prostate cancer (CaP) staging and prognosis. Proc AACR 1998; 39: 692.
12. Partin AW et al. The development of a neural network-based staging index for predicting organ-confined disease in men with newly diagnosed prostate cancer. J Urol 1998; 159(Suppl): 294.
13. Crawford ED et al. Artificial intelligence system in prediction of lymph node involvement in radical prostatectomy patients. J Urol 1999; 161(Suppl): 236.
14. Veltri RW et al. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. Semin Urol Oncol 1998; 16: 106-114.
15. Ragde H et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate cancer. Cancer 1998; 83: 989-1001.
16. Potter SR et al. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 1999; 54: 791-795.
17. Mattfeldt T, Kestler HA, Hautmann R, Gottfried HW. Prediction of prostatic cancer progression after radical prostatectomy using artificial neural networks: a feasibility study. BJU International 1999; 84: 316-323.
18. Menon M et al. Genetic adaptive neural network model to predict PSA progression following radical prostatectomy: a multi-institutional study. J Urol 1999; 161(Suppl): 359.
19. Rodvold DM. A software development process model for artificial neural networks in critical applications. Proceedings of the International Joint Consensus on Neural Networks 1999, Washington D.C., 1999, 87pp.
20. O'Dowd GJ et al. Update on the appropriate staging evaluation for newly diagnosed G prostate cancer. J Urol 1997; 158: 687-698.
21. Tewari A, Gosh M. Comparative study of bayesian and traditional modeling in the management of prostate cancer. 1999, submitted for publication.
22. Catalona WJ et al. Detection of prostate cancer with %fPSA and hK2 when PSA is 2-4ng/ml. J Urol 1999; 161(Suppl): 207.
23. Murphy GP et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998; 83: 2259-2269.
24. 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 1999; 85: 1586-15920.
25. Ikeda I, Miura T, Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol 1996; 77: 102-106.
26. Wolk A et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-915.
27. Veltri et al. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 1999; 53: 139-147.
28. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999; 53: 707-713.
29. Moul JW. Angiogenesis, p53, bel-2 and KI-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 1999; 35: 399-407.
30. Diaz JI et al. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology 1999; 53: 931-938.
31. Cote RJ et al. Association of p27 Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998; 90: 916-920.
32. Subong EN et al. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate 1999; 39: 298-304.
33. Bostwick DG, Iczkowski KA. Microvessel density in prostate cancen prognostic and therapeutic utility. Semin Urol Oncol 1998; 16: 118-123.
34. Veltri RW et al. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem Suppl 1994; 19: 249-258.